CORRESP Filing
PharmaCyte Biotech, Inc.
Date: Sept. 24, 2025 · CIK: 0001157075 · Accession: 0001683168-25-007214
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290311
Letter
PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, NV 89169
September 24, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jimmy McNamara
Re: PharmaCyte Biotech, Inc.
Registration Statement on Form S-3
Filed September 17, 2025
File No. 333-290311 (the "Registration Statement")
Acceleration Request
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, PharmaCyte Biotech, Inc. (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, September 26, 2025, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please contact Kenneth R. Koch of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6768 with any questions regarding this request.
Very truly yours,
PHARMACYTE BIOTECH, INC.
Show Raw Text
CORRESP 1 filename1.htm PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, NV 89169 September 24, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: PharmaCyte Biotech, Inc. Registration Statement on Form S-3 Filed September 17, 2025 File No. 333-290311 (the "Registration Statement") Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, PharmaCyte Biotech, Inc. (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, September 26, 2025, at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Kenneth R. Koch of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6768 with any questions regarding this request. Very truly yours, PHARMACYTE BIOTECH, INC. /s/ Joshua N. Silverman Joshua N. Silverman Chief Executive Officer, President and Chairman of the Board cc: Mintz, Levin. Cohn. Ferris. Glovsky and Popeo. P.C Kenneth R. Koch, Esq. Daniel A. Bagliebter, Esq. Jeffrey D. Cohan, Esq.